New drug combo aims to fight Hard-to-Treat vulvar cancer
NCT ID NCT07290894
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing whether two drugs, pembrolizumab and lenvatinib, can shrink or control vulvar cancer that cannot be surgically removed. About 80 participants will receive the combination in 21-day cycles. The study will measure tumor response and track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab and Lenvatinib
What this could lead to
If successful, this combination could offer a new treatment option to shrink or control vulvar cancer that cannot be removed by surgery.
What could go wrong
This is an early Phase 2 trial with a small number of participants. The drugs may cause side effects, and it is not yet known if they will work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VULVA CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nation Cancer Institute of Naples, Division of Medical Oncology - Uro-Gynecology Department, Naples
RECRUITINGNaples, 80131, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••